Aquestive Therapeutics Inc (NASDAQ:AQST) has a beta value of 2.59 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $294.15M, closed the recent trade at $2.97 per share which meant it gained $0.07 on the day or 2.59% during that session. The AQST stock price is -95.29% off its 52-week high price of $5.80 and 24.58% above the 52-week low of $2.24. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.4 million shares traded. The 3-month trading volume is 1.65 million shares.
The consensus among analysts is that Aquestive Therapeutics Inc (AQST) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.16.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Sporting 2.59% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the AQST stock price touched $2.97 or saw a rise of 8.33%. Year-to-date, Aquestive Therapeutics Inc shares have moved -16.43%, while the 5-day performance has seen it change -7.61%. Over the past 30 days, the shares of Aquestive Therapeutics Inc (NASDAQ:AQST) have changed 12.26%. Short interest in the company has seen 10.23 million shares shorted with days to cover at 6.77.
Wall Street analysts have a consensus price target for the stock at $8.5, which means that the shares’ value could jump 65.06% from the levels at last check today. The projected low price target is $7.0 while the price target rests at a high of $10.0. In that case, then, we find that the latest price level in today’s session is -236.7% off the targeted high while a plunge would see the stock gain -135.69% from the levels at last check today.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
The company’s shares have lost -36.97% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -13.87%.
8 analysts offering their estimates for the company have set an average revenue estimate of 12.23M for the current quarter. 8 have an estimated revenue figure of 12.17M for the next ending quarter. Year-ago sales stood 12.05M and 20.1M respectively for this quarter and the next, and analysts expect sales will grow by 1.47% for the current quarter and -13.87% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 27.90% over the past 5 years. Earnings growth for 2025 is a modest -30.07% while over the next 5 years, the company’s earnings are expected to increase by 13.68%.
AQST Dividends
Aquestive Therapeutics Inc is expected to release its next earnings report on 2025-Mar-04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
Insiders own 5.04% of the company shares, while shares held by institutions stand at 48.33% with a share float percentage of 50.90%. Investors are also buoyed by the number of investors in a company, with Aquestive Therapeutics Inc having a total of 151.0 institutions that hold shares in the company. The top two institutional holders are BRATTON CAPITAL MANAGEMENT, L.P. with over 9.81 million shares worth more than $25.51 million. As of 2024-06-30, BRATTON CAPITAL MANAGEMENT, L.P. held 10.7918% of shares outstanding.
The other major institutional holder is VR ADVISER, LLC, with the holding of over 5.56 million shares as of 2024-06-30. The firm’s total holdings are worth over $14.44 million and represent 6.1109% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.43% shares in the company for having 2.4 shares of worth $7.18 million while later fund manager owns 1.92 shares of worth $5.72 million as of Feb 28, 2025, which makes it owner of about 1.94% of company’s outstanding stock.
